21.72
Beam Therapeutics Inc (BEAM) 最新ニュース
Will Beam Therapeutics Inc. stock benefit from interest rate changesFree Market Dynamics Reports - jammulinksnews.com
What makes Beam Therapeutics Inc. stock attractive to long term investorsSuperior stock selection - jammulinksnews.com
What institutions are buying Beam Therapeutics Inc. stock nowOutperformance with explosive growth - jammulinksnews.com
What analysts say about Beam Therapeutics Inc. stockFree Popular Stock Recommendations - PrintWeekIndia
Trading (BEAM) With Integrated Risk Controls - news.stocktradersdaily.com
Can Beam Therapeutics Inc. stock recover from recent declineFree Smart Trading Workshop - jammulinksnews.com
Beam Therapeutics Inc. Stock Analysis and ForecastFree Stock Movement Tracking - Autocar Professional
What drives Beam Therapeutics Inc. stock priceDynamic investment opportunities - jammulinksnews.com
Is Beam Therapeutics Inc. a good long term investmentRobust financial gains - jammulinksnews.com
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
Beam Therapeutics (BEAM) Announces Acquisition of an Early-Stage Life Sciences Company - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
(BEAM) Trading Report - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - MSN
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT - MSN
Cathie Wood’s ARK ETF bolsters Beam stock, sheds Roblox - Investing.com
Beam Therapeutics: A Base Editing Breakthrough With Catalysts to Ignite Value - AInvest
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease Trial - MSN
Beam Therapeutics Acquires Early-Stage Life Sciences Firm - The Globe and Mail
H.C. Wainwright reiterates Buy rating on Beam Therapeutics stock at $80 target - Investing.com
Beam Therapeutics: A Contrarian Opportunity in Gene Editing Amid Russell Reconstitution - AInvest
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Beam Therapeutics Inc.(NasdaqGS: BEAM) dropped from Russell 3000 Value Index - MarketScreener
3 Promising Genomics Stocks to Keep an Eye On in 2025 - The Globe and Mail
大文字化:
|
ボリューム (24 時間):